3-(1,3-苯并二恶唑-5-基)-1-(顺式-3,5-二甲基-1-哌啶基)-3-(2-羟基-4,6-二甲氧基苯基)-1-丙酮 | 1334526-14-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3-(1,3-苯并二恶唑-5-基)-1-(顺式-3,5-二甲基-1-哌啶基)-3-(2-羟基-4,6-二甲氧基苯基)-1-丙酮
• 英文名称: 3-(benzo[d][1,3]dioxol-5-yl)-1-(cis-3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one
• 英文别名: ML209；(inverted exclamation markA)-ML 209；3-(1,3-benzodioxol-5-yl)-1-[(3S,5R)-3,5-dimethylpiperidin-1-yl]-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one
• CAS: 1334526-14-5
• 化学式: C₂₅H₃₁NO₆
• 分子量: 441.524
• InChiKey: YEKVAIMYYCZDLI-MCPYQZEQSA-N

物化性质

• 沸点：
  656.2±55.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：100 mM

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(1,3-苯并二恶唑-5-基)-1-(顺式-3,5-二甲基-1-哌啶基)-3-(2-羟基-4,6-二甲氧基苯基)-1-丙酮 在 IA Preparatory HPLC column 作用下， 以 乙醇 、 正己烷 为溶剂， 生成 SR-9805 、 (+)-3-(benzo[d][1,3]dioxol-5-yl)-1-(cis-3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one
  参考文献：
  名称：

  Identification of Potent and Selective Diphenylpropanamide RORγ Inhibitors

  摘要：

  Retinoic acid-related orphan receptor ROR gamma t plays a pivotal role in the differentiation of T(H)17 cells. Antagonizing ROR gamma t transcriptional activity is a potential means to treat T(H)17-related autoimmune diseases. Herein, we describe the identification of a series of diphenylpropanamides as novel and selective ROR gamma antagonists. Diphenylpropanamide 4n inhibited the transcriptional activity of ROR gamma t, but not ROR alpha, in cells. In addition, it suppressed human T(H)17 cell differentiation at submicromolar concentrations.

  DOI：

  10.1021/ml300286h
• 作为产物：
  描述：

  3,4-methylenedioxy-trans-cinnamic acid 在 三氟乙酸 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 12.0h， 生成 3-(1,3-苯并二恶唑-5-基)-1-(顺式-3,5-二甲基-1-哌啶基)-3-(2-羟基-4,6-二甲氧基苯基)-1-丙酮
  参考文献：
  名称：

  Identification of Potent and Selective Diphenylpropanamide RORγ Inhibitors

  摘要：

  Retinoic acid-related orphan receptor ROR gamma t plays a pivotal role in the differentiation of T(H)17 cells. Antagonizing ROR gamma t transcriptional activity is a potential means to treat T(H)17-related autoimmune diseases. Herein, we describe the identification of a series of diphenylpropanamides as novel and selective ROR gamma antagonists. Diphenylpropanamide 4n inhibited the transcriptional activity of ROR gamma t, but not ROR alpha, in cells. In addition, it suppressed human T(H)17 cell differentiation at submicromolar concentrations.

  DOI：

  10.1021/ml300286h

文献信息

• AMIDO COMPOUNDS AS RORYT MODULATORS AND USES THEREOF
  申请人：New York University

  公开号：EP3002008A1

  公开（公告）日：2016-04-06

  Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

  本发明公开了具有下式表示的氨基化合物： 其中 n1、n2、R1a、R1b、R2、R3、R4、R5 和 R6 如本文所述。这些化合物可制备成药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，包括非限制性的炎症、自身免疫性疾病、癌症和移植物抗宿主疾病。
• Amido compounds as RORγt modulators and uses thereof
  申请人：New York University

  公开号：US10561666B2

  公开（公告）日：2020-02-18

  Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

  本发明公开了具有下式表示的氨基化合物： 其中 n1、n2、R1a、R1b、R2、R3、R4、R5 和 R6 如本文所述。这些化合物可制备成药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，包括非限制性的炎症、自身免疫性疾病、癌症和移植物抗宿主疾病。
• Methods for treating cancer with RORγ inhibitors
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US10959984B2

  公开（公告）日：2021-03-30

  The present invention provides compositions, methods, and kits comprising one or more RORγ inhibitors, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, lymphoma, and glioma.

  本发明提供了包含一种或多种RORγ抑制剂的组合物、方法和试剂盒，单独或与一种或多种抗癌药物（如抗雄激素药物）联合使用，可用于治疗癌症，如前列腺癌，如阉割耐药前列腺癌（CRPC），以及许多其他类型的癌症，包括肺癌、乳腺癌、肝癌、卵巢癌、子宫内膜癌、膀胱癌、结肠癌、淋巴瘤和胶质瘤。
• AMIDO COMPOUNDS AS RORyT MODULATORS AND USES THEREOF
  申请人：Littman Dan

  公开号：US20130085162A1

  公开（公告）日：2013-04-04

  Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R 1a , R 1b , R 2 , R 3 , R 4 , R 5 , and R 6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.
• METHODS OF TREATING OR PREVENTING BRAIN DAMAGE DUE TO HYPOXIC-ISCHEMIA
  申请人：EMORY UNIVERSITY

  公开号：US20160317473A1

  公开（公告）日：2016-11-03

  This disclosure relates to managing brain injury. In certain embodiments, this disclosure relates to methods comprising administering an effective amount of an inhibitor of sphingosine-1-phoshate signaling, an inhibitor of retinoic-acid-receptor-related orphan receptors α or γ, and/or an inhibitor of tPA microglial activation to a subject in need thereof. Typically, the subject is a neonate or a neonate born prematurely.